Evidence map›Paper›PMID 41750307›Full record

ReviewBiomolecules2026

Galanin Receptors: G Protein-Dependent Signaling and Beyond.

Judit Oláh, Eszter Soltész-Katona, Hana Kaci, Gábor Turu, László Hunyady

Abstract readReview
In one paragraph

Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Judit OláhInstitute of Molecular Life Sciences, Centre of Excellence of the Hungarian Academy of Sciences, HUN-REN Research Centre for Natural Sciences, 1117 Budapest, Hungary.ORCID 0000-0002-2470-8631
Eszter Soltész-KatonaInstitute of Molecular Life Sciences, Centre of Excellence of the Hungarian Academy of Sciences, HUN-REN Research Centre for Natural Sciences, 1117 Budapest, Hungary.
Hana KaciInstitute of Molecular Life Sciences, Centre of Excellence of the Hungarian Academy of Sciences, HUN-REN Research Centre for Natural Sciences, 1117 Budapest, Hungary.ORCID 0000-0003-4571-3568
Gábor TuruInstitute of Molecular Life Sciences, Centre of Excellence of the Hungarian Academy of Sciences, HUN-REN Research Centre for Natural Sciences, 1117 Budapest, Hungary.ORCID 0000-0002-4421-3812
László HunyadyInstitute of Molecular Life Sciences, Centre of Excellence of the Hungarian Academy of Sciences, HUN-REN Research Centre for Natural Sciences, 1117 Budapest, Hungary.ORCID 0000-0002-8438-7251

Funding

Hungarian National Research, Development and Innovation Office 2025-1.2.3-TÉT-IPARI-KR-2025-00029Hungarian National Research, Development and Innovation Office grant NKFI ADVANCED 153452 and 151284, NKFI FK 138862
6 · The paper itself

Abstract

The G protein-coupled galanin receptors include three different subtypes: galanin receptor 1, 2 and 3 (GalR1, GalR2, GalR3). The neuropeptide galanin is the principal natural agonist of the galanin receptors, the so-called galaninergic system. Galanin-like peptide and spexin have also been identified as natural ligands of the galanin receptors. Galanin receptors are widely expressed in the brain; however, they can be found in other tissues, such as the skeletal muscle, the heart, and the gastrointestinal tract. The galaninergic system regulates diverse biological processes, including feeding behavior, neuroprotection, learning, memory, cardiovascular and renal function, and nociception. Its dysregulation is associated with various diseases, such as Alzheimer's disease, diabetes mellitus, epilepsy, depression, and cancer. The stimulation of GalR1 and GalR3 leads to the Gαi/o-type G protein-mediated inhibition of cyclic AMP/protein kinase A, whereas GalR2 stimulation initiates phospholipase C activation via Gαq/11-type G proteins. A galanin-activated β-arrestin-dependent pathway has also been described for GalR2. In this review, we summarize the recent advances concerning galanin receptor signaling, including both the G protein-dependent and -independent pathways. A better understanding of the complex interplay of the signaling molecules, receptors, and various signaling pathways is crucial for the future development of specific agonists with therapeutic potential.

Indexed as

GTP-Binding ProteinsReceptors, GalaninSignal TransductionAnimalsGalaninHumansGalaninGTP-Binding ProteinsReceptors, Galaninbiased signalinggalanin receptorpathological functionreceptor structureβ-arrestin

Identifiers

PMID41750307
PMCPMC12938440

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.